Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims about grapefruit components inhibiting CYP3A4 and increasing atorvastatin plasma concentrations are supported by the provided label excerpt (7.2). However, multiple mechanistic, causal, and generalization claims are not supported by the supplied prescribing information, and one claim misframes the direction of effect (cholesterol-lowering).
Category Scores
Accurate Statements
Grapefruit interaction can lead to increased levels of atorvastatin in the blood.
Label 7.2 Grapefruit Juice: grapefruit components inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin.
Unsupported Statements
Increased atorvastatin levels from grapefruit interaction can potentially cause liver damage as a result of increased toxicity.
The provided label excerpt (7.2) supports increased plasma concentrations but does not link grapefruit-related atorvastatin exposure to liver damage/toxicity.
Grapefruit juice is the main cause of the interaction with Lipitor.
The label excerpt mentions grapefruit juice consumption and components but does not state it is the 'main cause' of the interaction.
Furanocoumarins in grapefruit block the action of the enzyme CYP3A4 in the gut.
The provided excerpt states grapefruit components inhibit CYP3A4 but does not mention furanocoumarins or specify 'in the gut'.
CYP3A4 helps break down atorvastatin in the gut.
Not stated in the provided excerpt.
Normally, CYP3A4 helps atorvastatin be absorbed into the bloodstream in a controlled manner.
Not stated in the provided excerpt.
When CYP3A4 is blocked, atorvastatin accumulates in the gut.
Not stated in the provided excerpt; only increased plasma concentrations are mentioned.
When CYP3A4 is blocked, atorvastatin is more readily absorbed into the bloodstream.
The label excerpt supports increased plasma concentrations but does not explicitly describe 'more readily' absorption or the exact absorption mechanism.
The interaction can occur in anyone who consumes grapefruit or grapefruit juice regularly while taking Lipitor.
The label excerpt highlights increased concentrations especially with excessive grapefruit juice consumption (>1.2 liters/day) but does not support the broad 'anyone' / 'regularly' phrasing.
The frequency of the interaction depends on the amount and frequency of grapefruit consumption and the individual's genetics.
The provided excerpt supports increased concentrations with excessive consumption but does not discuss interaction frequency in those terms or genetics.
If grapefruit or grapefruit juice is consumed while taking Lipitor, patients should inform a doctor or pharmacist.
Not present in the provided label sections.
In some cases, a doctor may need to lower the dose of Lipitor.
Not supported as grapefruit-specific dose adjustment in the provided sections.
Other cholesterol-lowering medications, such as statins, may also be affected by grapefruit consumption.
The provided excerpts are specific to atorvastatin; no other statins are addressed.
Simvastatin (Zocor) is affected by grapefruit juice.
Not mentioned in the provided excerpts.
The interaction between grapefruit juice and simvastatin is less pronounced than with atorvastatin.
No information about simvastatin or comparative magnitude is provided in the supplied excerpts.
Contradictions
Low
AI Statement
Grapefruit can interfere with Lipitor (atorvastatin) in the body to lower cholesterol levels.
Label Reference
Label 7.2 Grapefruit Juice supports increased plasma concentrations of atorvastatin via CYP3A4 inhibition; it does not state grapefruit interferes to lower cholesterol levels.
Important Omissions
The label excerpt (7.2) specifies 'especially with excessive grapefruit juice consumption (>1.2 liters per day)'; the provided claims do not incorporate this quantitative threshold.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Overextended claims (e.g., grapefruit-related liver damage/toxicity; broad 'anyone' regular consumption; unsupported mechanistic details) could mislead risk perception. Some interaction directionality is also misstated (cholesterol-lowering), though the excerpt does support increased atorvastatin exposure.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple grapefruit–atorvastatin mechanistic/causal/generalization claims are not supported by the provided label excerpts, and one statement misframes the expected effect as cholesterol-lowering rather than increased atorvastatin exposure.
Suggested Improvement
Restrict claims to what the provided label supports: grapefruit components inhibit CYP3A4 and can increase atorvastatin plasma concentrations, especially with excessive grapefruit juice consumption (>1.2 liters/day). Avoid attributing grapefruit-specific liver damage/toxicity, avoid unsupported mechanistic detail (e.g., furanocoumarins, gut accumulation), and avoid broad/general comparative or other-statins claims not present in the supplied label.